Induction chemotherapy plus radiotherapy followed by surgery, evaluated in a number of phase II studies, is an effective treatment for patients with stage IIIA non-small cell lung cancer (NSCLC). The ongoing phase III National Cancer Institute Intergroup study is evaluating concurrent chemotherapy (cisplatin + etoposide)/radiotherapy followed by either surgery or additional radiotherapy followed by 2 additional cycles of chemotherapy in patients with stage IIIA disease. This study will help define the role of surgery and radiotherapy as part of the multimodality therapy of locoregional advanced NSCLC.
|Original language||English (US)|
|Journal||Cancer Chemotherapy and Pharmacology, Supplement|
|State||Published - Aug 1 1998|
- Combined-modality treatment
- Stage IIIA
ASJC Scopus subject areas
- Cancer Research